NCT06477263

NeuroCytotron in the Treatment of Autism Spectrum Disorder

Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder: A Pilot Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Neurocytonix, Inc. · Industry
• Sex: All
• Age: 3 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder

Detailed description

Experimental, pilot, one-arm, open-label, single-center, 13-month, single-center study to evaluate the effect of NCX neuronal regeneration treatment in subjects with Autism Spectrum Disorder (ASD) to explore the therapeutic effects of NeuroCytonix neuronal regeneration technology on ASD symptoms. Specific objectives include collecting preliminary safety and efficacy data, assessing appropriate dosing, and measuring the impact on participants' quality of life after treatment.

Conditions

• Autism Spectrum Disorder

Interventions

Type	Name	Description
DEVICE	Neurocytotron	Neuronal regeneration treatment

Timeline

• Start date: 2024-07-15
• Primary completion: 2025-03-06
• Completion: 2025-09-30
• First posted: 2024-06-27
• Last updated: 2025-02-06

Locations

1 site across 1 country: Mexico